Milestone Pharmaceuticals (MIST) has released an update.
Milestone Pharmaceuticals has announced a promising update with the resubmission of their New Drug Application for etripamil, targeting PSVT treatment, following a successful dialogue with the FDA. The company also shared encouraging clinical trial results, showing a high conversion rate to normal heart rhythm post-administration of the drug. Moreover, they have reported sufficient cash reserves anticipated to support operations well into 2026.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
